Showing 1 - 3 results of 3 for search 'Thomas Wegman', query time: 0.03s
Refine Results
-
1
P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a su... by Richard Furie, Peter Nash, Amit Saxena, Thomas Dörner, Subhashis Banerjee, Joan Merrill, Marilyn Pike, Coburn Hobar, Samantha Pomponi, Ravi Koti, Thomas Wegman
Published 2024-03-01Article -
2
O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhib... by Laura Geraldino-Pardilla, Subhashis Banerjee, Ann E Clarke, Eric Morand, Cristina Arriens, Ronald van Vollenhoven, Coburn Hobar, Samantha Pomponi, Ravi Koti, Thomas Wegman
Published 2024-03-01Article -
3
P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial by Joseph F Merola, Subhashis Banerjee, Eric Morand, Piotr Leszczyński, Marilyn Pike, Ronald F van Vollenhoven, Coburn Hobar, Kathryn H Dao, Samantha Pomponi, Matthew J Colombo, Ravi Koti, Thomas Wegman
Published 2024-03-01Article